Lumida
/ZYME
⌘K
Zymeworks Inc

Zymeworks Inc

ZYME
$26.24USD-0.74%-0.20 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

7.8x

DAY RANGE

$26 – $27

52W RANGE

$15
$31

AI Summary

Stalk
StalkMedium

After a sharp markup and subsequent peak above the fast EMAs, ZYME has pulled back into a support confluence around the 9 EMA, 20 EMA, and 50 SMA. The medium-term bias remains bullish within a broader long-term uptrend, but short-term momentum is negative as price trades below the fast EMAs and the RSI has rolled over. Execution should be deferred, stalking for stabilization at the EMA/SMA zone before initiating a position. Key risks include a breakdown below the 50 SMA and 200 DMA that would shift the medium-term structure.

  • Xanadatamab PDUFA on Aug 25, 2026 could yield $250M milestone payment
  • Phase 1 ZW191 data show 68% response rate in heavily pre-treated ovarian patients
  • Negative earnings yield and net loss of $44.2M in Q1 2026 hinder returns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$412.5M$76.0M$76.3M$106.0M
YoY %-81.6%+0.4%+38.9%
P / Sales1.2x9.4x14.6x18.7x
EV / Sales0.6x8.9x15.3x19.1x
Gross Profit, Adj.$412.5M$76.0M$76.3M$106.0M
YoY %-81.6%+0.4%+38.9%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit0.6x8.9x15.3x19.1x
EBITDA, Adj.$137.8M$-127.9M$-111.1M$-84.8M
YoY %-192.8%+13.1%+23.7%
Margin %33.4%-168.2%-145.7%-80.0%
EV / EBITDA1.8x-5.3x-10.5x-23.8x
EBIT$130.5M$-138.1M$-137.1M$-92.5M
YoY %-205.8%+0.7%+32.5%
Margin %31.6%-181.6%-179.7%-87.3%
EV / EBIT1.9x-4.9x-8.5x-21.9x
Net Income$124.3M$-118.7M$-122.7M$-81.1M
YoY %-195.4%-3.4%+33.9%
Net Margin30.1%-156.1%-160.8%-76.6%
EPS (GAAP)$1.90-$1.72-$1.62-$1.08
YoY %-190.5%+5.8%+33.3%